These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 21093896

  • 1. ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer.
    Park JS, Jeon EK, Chun SH, Won HS, Lee A, Hur SY, Lee KH, Bae SN, Yoon SC, Hong SH.
    Gynecol Oncol; 2011 Feb; 120(2):275-9. PubMed ID: 21093896
    [Abstract] [Full Text] [Related]

  • 2. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
    Darcy KM, Tian C, Reed E.
    Cancer Res; 2007 May 01; 67(9):4474-81. PubMed ID: 17483363
    [Abstract] [Full Text] [Related]

  • 3. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
    Sodja E, Knez L, Kern I, Ovčariček T, Sadikov A, Cufer T.
    Eur J Cancer; 2012 Dec 01; 48(18):3378-85. PubMed ID: 22795264
    [Abstract] [Full Text] [Related]

  • 4. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
    Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC, Fouret P.
    Clin Cancer Res; 2007 Jul 01; 13(13):3855-9. PubMed ID: 17606717
    [Abstract] [Full Text] [Related]

  • 5. Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin.
    Shao YY, Kuo KT, Hu FC, Lu YS, Huang CS, Liau JY, Lee WC, Hsu C, Kuo WH, Chang KJ, Lin CH, Cheng AL.
    Jpn J Clin Oncol; 2010 Apr 01; 40(4):286-93. PubMed ID: 20085902
    [Abstract] [Full Text] [Related]

  • 6. Neoadjuvant cisplatin and etoposide followed by radical hysterectomy for stage 1B-2B cervical cancer.
    Bae JH, Lee SJ, Lee A, Park YG, Bae SN, Park JS, Namkoong SE.
    Gynecol Oncol; 2008 Dec 01; 111(3):444-8. PubMed ID: 18829085
    [Abstract] [Full Text] [Related]

  • 7. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy.
    Ozcan MF, Dizdar O, Dincer N, Balcı S, Guler G, Gok B, Pektas G, Seker MM, Aksoy S, Arslan C, Yalcin S, Balbay MD.
    Urol Oncol; 2013 Nov 01; 31(8):1709-15. PubMed ID: 22863869
    [Abstract] [Full Text] [Related]

  • 8. Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy.
    Gadducci A, Teti G, Barsotti C, Tana R, Fanucchi A, Orlandini C, Fabrini MG, Genazzani AR.
    Anticancer Res; 2010 Jan 01; 30(1):201-8. PubMed ID: 20150636
    [Abstract] [Full Text] [Related]

  • 9. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C, Ren S, Zhou S, Zhang L, Su C, Zhang Z, Deng Q, Zhang J.
    Jpn J Clin Oncol; 2010 Oct 01; 40(10):954-60. PubMed ID: 20462983
    [Abstract] [Full Text] [Related]

  • 10. Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma.
    Scheil-Bertram S, Tylus-Schaaf P, du Bois A, Harter P, Oppitz M, Ewald-Riegler N, Fisseler-Eckhoff A.
    Gynecol Oncol; 2010 Nov 01; 119(2):325-31. PubMed ID: 20728204
    [Abstract] [Full Text] [Related]

  • 11. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
    Huang MY, Tsai HL, Lin CH, Huang CW, Ma CJ, Huang CM, Chai CY, Wang JY.
    J Surg Oncol; 2013 Dec 01; 108(7):457-64. PubMed ID: 23996617
    [Abstract] [Full Text] [Related]

  • 12. Pretreatment serum hemoglobin level as a predictive factor of response to neoadjuvant chemotherapy in patients with locally advanced squamous cervical carcinoma: a preliminary report.
    Fuso L, Mazzola S, Marocco F, Ferrero A, Dompè D, Carus AP, Zola P.
    Gynecol Oncol; 2005 Dec 01; 99(3 Suppl 1):S187-91. PubMed ID: 16185756
    [Abstract] [Full Text] [Related]

  • 13. Neoadjuvant chemotherapy followed by radical surgery in patients affected by FIGO stage IVA cervical cancer.
    Benedetti Panici P, Bellati F, Manci N, Pernice M, Plotti F, Di Donato V, Calcagno M, Zullo MA, Muzii L, Angioli R.
    Ann Surg Oncol; 2007 Sep 01; 14(9):2643-8. PubMed ID: 17562114
    [Abstract] [Full Text] [Related]

  • 14. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP, Liu BR, Shi MQ, Liu XZ, Hu WJ, Zou ZY, Wei J.
    Zhonghua Zhong Liu Za Zhi; 2009 Jan 01; 31(1):33-7. PubMed ID: 19538866
    [Abstract] [Full Text] [Related]

  • 15. Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer.
    Ikeda S, Takabe K, Suzuki K.
    Pathol Int; 2009 Dec 01; 59(12):863-7. PubMed ID: 20021611
    [Abstract] [Full Text] [Related]

  • 16. [Evaluation of neoadjuvant chemotherapy for locally advanced cervical cancinoma].
    Cheng XD, Lü WG, Ye F, Chen HZ, Xie X.
    Zhonghua Fu Chan Ke Za Zhi; 2006 Feb 01; 41(2):95-8. PubMed ID: 16640856
    [Abstract] [Full Text] [Related]

  • 17. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, Chen B, Cheng L, Lu Z, Ji J, Zhou Y.
    Am J Clin Oncol; 2010 Oct 01; 33(5):489-94. PubMed ID: 20351547
    [Abstract] [Full Text] [Related]

  • 18. Neoadjuvant treatment of locally advanced carcinoma of the uterine cervix with epirubicin, paclitaxel and cisplatin.
    D'Agostino G, Distefano M, Greggi S, Salerno M, Ferrandina G, Poerio A, Mancuso S, Scambia G.
    Cancer Chemother Pharmacol; 2002 Mar 01; 49(3):256-60. PubMed ID: 11935219
    [Abstract] [Full Text] [Related]

  • 19. Excision repair cross-complementation group 1 expression predicts response and survival in locally advanced cervical carcinoma patients treated with concurrent chemoradiotherapy.
    Liang ZL, Song EK, Ko YB, Lee NR, Yhim HY, Noh HT, Yun HJ, Suh KS, Jo DY, Kim S, Kim JS, Kim JM, Lee HJ.
    Histopathology; 2011 Sep 01; 59(3):564-7. PubMed ID: 22034895
    [No Abstract] [Full Text] [Related]

  • 20. [Neoadjuvant chemotherapy in locally advanced squamous carcinoma of the uterine cervix (IB2 - IIIB stage)].
    Kornovski Ia, Ianeva R, Gorchev G, Tsekov Kh, Uzunov S, Filev S.
    Akush Ginekol (Sofiia); 2002 Sep 01; 41(4):39-44. PubMed ID: 12516261
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.